Gland Pharma Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "UFR Q3FY26".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma has submitted a press release to NSE dated January 28, 2026, titled 'UFR Q3FY26', indicating the disclosure of its unaudited financial results for the third quarter of FY26 (quarter ending December 2025). This is a standard regulatory filing informing the exchange that quarterly results have been published. The headline itself does not include specific financial numbers; investors need to refer to the detailed press release for revenue, profit, margins, and segment-wise performance.
Routine quarterly results disclosure — the actual numbers and management commentary in the detailed press release will determine any near-term stock price reaction. Shareholders should review the full results for earnings growth, margin trends, and guidance.